Categories
Archives
- 2026
- 2025
- 2024
- 2023
Aug
01
Evolving Expectations for Dermatological Conditions
Jul
21
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Jun
27
Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis
Jun
27
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
Jun
14
Recognizing Ethical Leadership at UCB
Jun
02
Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome
Jun
01
Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community
Apr
27
Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients
Apr
21
Earth Day 2023: Our Commitment to Sustainability in the Workplace